RecruitingPhase 2 / Phase 3interventionalRules rewrite

Phase 2 / Phase 3: testing Taurine for Long COVID

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.

Official registry: https://clinicaltrials.gov/study/NCT06721949 · University of Alberta · enrollment listed as 300

What this phase means

Phase 2/3: earlier tests looked promising enough to expand. This stage asks, in a larger group, whether the treatment really works and is safe enough to seek approval.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Taurine, or Placebo. The registry lists allocation as randomized. The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity.

They plan to enroll about 300 people at 5 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Taurine Supplementation as a Novel Therapeutic Approach for Neurocognitive Symptoms in Long COVID

Interventions: Taurine, Placebo

Primary outcome (registry wording): Mean change in Modified Fatigue Impact Scale (MFIS) from baseline to three months

Who it is for (from inclusion criteria)

Ages 18 Years to any
If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks)
Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms
Lingering symptoms from COVID-19 present at the time of randomization

Who the registry excludes

Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19
Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital
Contraindications to the study intervention
Currently already on study intervention(s)
Co-enrolment in another treatment trial (co-enrolment in an watch-and-measure (no experimental treatment required) study is permitted)
Currently pregnant or breastfeeding
The participant is currently enrolled in another clinical trial to treat neurocognitive symptoms in LC

Public study contact (from the registry)

Lawrence Richer, MD, MSc

780-492-0943

lricher@ualberta.ca

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

5 listed

University of Alberta Hospital, Kaye Edmonton Clinic — Edmonton, Alberta, Canada (recruiting)
BC Women's Hospital — Vancouver, British Columbia, Canada (recruiting)
University Health Network — Toronto, Ontario, Canada (recruiting)
Institut de recherches cliniques de Montréal — Montreal, Quebec, Canada (recruiting)
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke — Sherbrooke, Quebec, Canada (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT06721949 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06721949?

Phase 2 / Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06721949?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary